Christoph T. Ellebrecht

Author

Also Known As

C Ellebrecht, C. Ellebrecht, C. T. Ellebrecht, C.T. Ellebrecht, Christoph Ellebrecht, Christoph T Ellebrecht, Christoph T. Ellebrecht

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Wake Forest University Children's Hospital of Philadelphia University of Lübeck Eastern Virginia Medical School

About

Christoph T. Ellebrecht is an author at University of Pennsylvania specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.3K
2	Immunology	10	10	1.3K
3	Allergy	4	4	895
4	Cell Biology	4	4	968
5	Clinical Immunology	1	1	140

Christoph T. Ellebrecht

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Christoph T. Ellebrecht, Vijay Bhoj, Arben Nace, Science T-regulatory CellImmunologyImmunologic MechanismAntigen ProcessingT Cells	2016	670
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, Blood	2016	258
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells Sangwook Oh, Xuming Mao, Sílvio M. Vieira, Nature Biotechnology	2023	149
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris Jinmin Lee, Daniel K. Lundgren, Xuming Mao, Journal of Clinical Investigation Clinical ImmunologyAdaptive Immune SystemImmunologyImmune RegulationPathology	2020	140
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor Rachel S. Leibman, Max W. Richardson, Christoph T. Ellebrecht, PLoS Pathogens Adaptive Immune SystemImmunologyAntigen ProcessingCd4 T Cell ResponsesT Cells	2017	130
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments Joel M. Gelfand, April W. Armstrong, Stacie Bell, Journal of the American Academy of Dermatology VaccinationMedicineVaccine SurveillancePsoriatic DiseaseImmunology	2021	98
Enrichment of total serum IgG4 in patients with pemphigus Takeru Funakoshi, Luisa Lunardon, Christoph T. Ellebrecht, British Journal of Dermatology	2012	62
Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris Christoph T. Ellebrecht, Eun Jung Choi, David Allman, JAMA Dermatology ImmunodeficienciesImmunologyBiological TherapyImmunotherapeuticsPharmacotherapy	2014	60
Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients Michael Jeffrey Cho, Agnes S. Lo, Xuming Mao, Nature Communications InflammationImmunogeneticsPemphigus Vulgaris AutoantibodiesAutoimmune DiseaseAutoantibody Production	2014	55
Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics Jing Chen, Qi Zheng, Christoph M. Hammers, Cell Reports	2017	55

Page 1